This inventor holds 57 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Antibody Therapeutics. Top assignees: Sorrento Therapeutics, Inc., Medtronic Minimed, Inc., Huntsman Petrochemical Corporation. Active years: 2003-2026.
Location History:
- Los Angeles, CA (US) (2005 - 2010)
- Round Rock, OH (US) (2011)
- Woodland Hills, CA (US) (2003 - 2015)
- Round Rock, TX (US) (2004 - 2017)
- San Diego, CA (US) (2015 - 2024)
Company Filing History:
33 out of 114 
17 out of 1,262 
2 out of 258 
Years Active: 2003-2026
Areas of Expertise:
Title: John Dixon Gray: Innovator in Antibody Therapeutics
Introduction: John Dixon Gray is a prominent figure in the field of biotechnology, particularly known for his innovations in the development of fully human antibodies. Based in San Diego, CA, he holds an impressive portfolio of 34 patents attributed to his groundbreaking work. His inventions focus primarily on treatments for various cancers and diseases through advanced antibody therapeutics.
Latest Patents: Among his latest patents, Gray has made significant contributions with the development of fully human antibodies that bind to the vascular endothelial growth factor receptor 2 (VEGFR2). This innovation includes compositions and methods relating to anti-VEGFR2 antibodies, along with binding fragments and derivatives. These advancements pave the way for effective treatment and diagnostics of various cancers.
Another notable patent revolves around antibody therapeutics that bind CD38. This includes the disclosure of fully human antibodies targeting CD38, along with their respective binding fragments and derivatives. The methods outlined in these patents also encompass the creation of nucleic acids encoding these antibodies, providing a comprehensive approach to treating diseases linked to CD38.
Career Highlights: John Gray has played a significant role in various companies throughout his career, including Sorrento Therapeutics, Inc. and Vivasor, Inc. His work at these establishments underscores his commitment to advancing medical science through innovative biotechnological solutions.
Collaborations: Collaboration often enhances the innovation process, and Gray has worked alongside notable colleagues in the field, including Heyue Zhou and Barbara Anne Swanson. These partnerships have contributed to the successful development of his patented technologies and therapeutics.
Conclusion: John Dixon Gray is a key innovator in the field of biotechnology, specializing in antibody therapeutics that have the potential to transform cancer treatment. His extensive patent portfolio stands as a testament to his contributions to medical science, showcasing his commitment to improving therapies for patients facing various health challenges.